Changing the paradigm for treatment intensification; combination therapy in type 2 diabetes (T2D)

The clinical benefits of IDegLira in DUAL VII™ were achieved while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy.

This session will include:

  • The definition and need for insulin intensification in patients with T2D
  • The complementing benefits of insulin and GLP1-RA therapy in patients with T2D
  • The available clinical evidence for Xultophy® (100 U/ml Insulin Degludec + 3.6 mg/ml Liraglutide), combination therapy in type 2 diabetes, and practical consideration for clinical use

Xultophy® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other oral medicinal products for the treatment of diabetes.

Date of Prep: October 2019 (UK19OZM00262)

*This is a promotional symposium organised and funded by Novo Nordisk. Prescribing information for all relevant products will be made available during the meeting

Tuesday 29 October 2019

11:00 - 11:20


Novo Nordisk Logo


Medical Affairs Manager Insulin, Novo Nordisk